Last reviewed · How we verify
NCT04613115
Relationship Between Arterial Variations and Patency of Arteriovenous Fistulae
trial in Arteriovenous Fistula in 1,000 participants. Completed in 30 June 2022.
30 June 2021
Quick facts
| Lead sponsor | Beijing Tongren Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 July 2020 |
| Primary completion | 30 June 2021 |
| Estimated completion | 30 June 2022 |
| Sites | 1 location across China |
Conditions studied
- Arteriovenous Fistula — all drugs for Arteriovenous Fistula →
- Ultrasound — all drugs for Ultrasound →
- Artery — all drugs for Artery →
Sponsor
Beijing Tongren Hospital
Who can join
14 and older, any sex, with Arteriovenous Fistula or Ultrasound. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In 2019, KDOQI considered that uremic patients with a life expectancy of more than one year should require hemodialysis as an effective renal replacement therapy before preparation of kidney transplantation. Arteriovenous fistula, as the lifeline of uremic patients, plays an important role in their daily hemodialysis. The patency of arteriovenous fistula is largely restricted by the inflow artery. According to available medical literatures, an incidence rate of variations in the branching pattern of the main arteries in the upper limb is ranged from 7.2% to 25.0%. and there is a large difference in the incidence rate between sex and race, furthermore, the incidence rate of variations in the branching pattern of the main arteries in the upper limb of Chinese is still unclear. The brachial artery is the main artery of the upper limb. It gives off two terminal branches at the distal end of the elbow crease, the radial and ulnar arteries, the former one often serves as an arterial inflow to create an arteriovenous fistula in the forearm. High bifurcation of the brachial artery (HBBA) seems to be a common variation which may result in immaturity or disfunction of arteriovenous fistulas. Therefore, the purpose of this study is to investigate the variations in the branching pattern of the main arteries in the upper limb of Chinese, in order to study on the hemodynamic changes, and their influence on the establishment, maturation and failure of arteriovenous fistulas in the upper limb.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04613115
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Arteriovenous Fistula
Currently open trials in the same condition.
- NCT07372027 — Single-Needle Distal Return for Long-Term Arteriovenous Fistula Care · NA · recruiting
- NCT06639451 — A Prospective, Multi-center Study to Evaluate Efficacy and Safety of BSJ020R in Treatment of AVF for Hemodialysis (RANGE · NA · active not recruiting
- NCT06527963 — DRug-coAted Balloon Compared With cuttinG balloON in Treatment of Arteriovenous Fistula Stenosis · recruiting
- NCT07314047 — The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation · NA · recruiting
- NCT06553443 — Randomised Clinical Trial Comparing Drug-coated Balloon to Plain Balloon for All Peripheral AVF Stenosis · Phase 3 · recruiting
Other Beijing Tongren Hospital trials
Trials by the same sponsor.
- NCT07499791 — Absorbable Drug-Eluting Lacrimal Sac Stent for Recurrent Chronic Dacryocystitis · Phase 2 · not yet recruiting
- NCT07524959 — Antagonism of Neostigmine in Continuous Infusion of Mivacurium · NA · not yet recruiting
- NCT07525466 — Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatm · Phase 1, PHASE2 · recruiting
- NCT07472764 — Auricular Acupressure for Reducing Postoperative Emergence Agitation in Preschool Children · NA · not yet recruiting
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04613115 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tongren Hospital
- Last refreshed: 21 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04613115.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing